S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis

Free Radical Biology and Medicine

Volumn 61, Issue , 2013, Pages 438-452

  Mead, Richard J ^a   Higginbottom, Adrian ^a   Allen, Scott P ^a   Kirby, Janine ^a   Bennett, Ellen ^a   Barber, Siân C ^a   Heath, Paul R ^a   Coluccia, Antonio ^b   Patel, Neelam ^a   Gardner, Iain ^c   Brancale, Andrea ^b   Grierson, Andrew J ^a   Shaw, Pamela J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c CERTARA UK LIMITED   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; motor neurone disease; neurodegeneration; Nrf2; preclinical pharmacology

Indexed keywords

2,6 DIHYDROXY 4 METHOXYTOLUENE; 3 ACETOXYPREG 16 EN 12,20 DIONE; 3 ALPHA HYDROXYGEDININ; 3BETA HYDROXYDEOXYDESACETOXY 7 OXOGEDUNIN; 4 METHOXYCHALCONE; ANDROGRAPHOLIDE; APOMORPHINE; COPPER ZINC SUPEROXIDE DISMUTASE; DALBERGIONE; DEOXYANDIROBIN LACTONE; HEME OXYGENASE 1; HYDROQUINONE; ISOGEDUNIN; LEVULINIC ACID; NEUROPROTECTIVE AGENT; PARTHENOLIDE; SECURININE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT RESPONSIVE ELEMENT; AREA UNDER THE CURVE; ARTICLE; ASTROCYTE; CENTRAL NERVOUS SYSTEM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG HALF LIFE; DRUG PENETRATION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHARMACOPHORE; PRIORITY JOURNAL; SURVIVAL; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 84878124559     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.04.018     Document Type: Article

References (76)

1. S.C. Barber, and P.J. Shaw Oxidative stress in ALS: key role in motor neuron injury and therapeutic target Free Radic. Biol. Med. 48 2010 629 641
2. C.A. Wood-Allum, and P.J. Shaw P.J. Shaw, M. Strong, Motor neuron disorders 2003 Butterworth Heinemann New York 285 313
3. P.R. Heath, and P.J. Shaw Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis Muscle Nerve 26 2002 438 458
4. J.S. Valentine, and P.J. Hart Misfolded CuZnSOD and amyotrophic lateral sclerosis Proc. Natl. Acad. Sci. USA 100 2003 3617 3622 (Pubitemid 36418082)
5. J.P. Crow, Y.Z. Ye, M. Strong, M. Kirk, S. Barnes, and J.S. Beckman Superoxide dismutase catalyzes nitration of tyrosines by peroxynitrite in the rod and head domains of neurofilament-L J. Neurochem. 69 1997 1945 1953 (Pubitemid 27452741)
6. S.D. Rao, and J.H. Weiss Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis Trends Neurosci 27 2004 17 23 (Pubitemid 38036974)
7. C. Colombrita, E. Zennaro, C. Fallini, M. Weber, A. Sommacal, E. Buratti, V. Silani, and A. Ratti TDP-43 is recruited to stress granules in conditions of oxidative insult J. Neurochem. 111 2009 1051 1061
8. J. Meyerowitz, S.J. Parker, L.J. Vella, D. Ng, K.A. Price, J.R. Liddell, A. Caragounis, Q.X. Li, C.L. Masters, T. Nonaka, M. Hasegawa, M.A. Bogoyevitch, K.M. Kanninen, P.J. Crouch, and A.R. White C-Jun N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress Mol. Neurodegener 6 2011 57
9. M. Benatar Lost in translation: treatment trials in the SOD1 mouse and in human ALS Neurobiol. Dis 26 2007 1 13 (Pubitemid 46437445)
10. S.C. Barber, R.J. Mead, and P.J. Shaw Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic target Biochim. Biophys. Acta 1762 2006 1051 1067 (Pubitemid 44750575)
11. R.W. Orrell, R.J. Lane, and M. Ross Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease Cochrane Database Syst. Rev. 2007 CD002829
12. A. Ascherio, M.G. Weisskopf, J. O'Reilly, E,E.J. Jacobs, M.L. McCullough, E.E. Calle, M. Cudkowicz, and M.J. Thun Vitamin E intake and risk of amyotrophic lateral sclerosis Ann. Neurol. 57 2005 104 110 (Pubitemid 40053321)
13. A. Storch, K. Burkhardt, A.C. Ludolph, and J. Schwarz Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism J. Neurochem. 75 2000 2259 2269
14. F.L. van Muiswinkel, and H.B. Kuiperij The Nrf2-ARE signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders Curr. Drug Targets CNS Neurol. Disord 4 2005 267 281 (Pubitemid 40754162)
15. J. Li, M.J. Calkins, D.A. Johnson, and J.A. Johnson Role of Nrf2-dependent ARE-driven antioxidant pathway in neuroprotection Methods Mol. Biol. 399 2007 67 78
16. T. Nguyen, P.J. Sherratt, H.C. Huang, C.S. Yang, and C.B. Pickett Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome J. Biol. Chem. 278 2003 4536 4541 (Pubitemid 36800950)
17. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, K. Igarashi, J.D. Engel, and M. Yamamoto Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain Genes Dev. 13 1999 76 86 (Pubitemid 29045117)
18. K.I. Tong, Y. Katoh, H. Kusunoki, K. Itoh, T. Tanaka, and M. Yamamoto Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model Mol. Cell. Biol. 26 2006 2887 2900
19. K.I. Tong, B. Padmanabhan, A. Kobayashi, C. Shang, Y. Hirotsu, S. Yokoyama, and M. Yamamoto Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response Mol. Cell. Biol. 27 2007 7511 7521 (Pubitemid 350033657)
20. A.M. Clement, M.D. Nguyen, E.A. Roberts, M.L. Garcia, S. Boillee, M. Rule, A.P. McMahon, W. Doucette, D. Siwek, R.J. Ferrante, R.H. Brown Jr., J.P. Julien, L.S. Goldstein, and D.W. Cleveland Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice Science 302 2003 113 117 (Pubitemid 37210700)
21. N. Wakabayashi, A.T. Dinkova-Kostova, W.D. Holtzclaw, M.I. Kang, A. Kobayashi, M. Yamamoto, T.W. Kensler, and P. Talalay Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers Proc. Natl. Acad. Sci. USA 101 2004 2040 2045 (Pubitemid 38229011)
22. M. McMahon, N. Thomas, K. Itoh, M. Yamamoto, and J.D. Hayes Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a tethering mechanism: a two-site interaction model for the Nrf2-Keap1 complex J. Biol. Chem 281 2006 24756 24768 (Pubitemid 44274250)
23. K.I. Tong, A. Kobayashi, F. Katsuoka, and M. Yamamoto Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism Biol. Chem. 387 2006 1311 1320 (Pubitemid 44691409)
24. M. McMahon, K. Itoh, M. Yamamoto, S.A. Chanas, C.J. Henderson, L.I. McLellan, C.R. Wolf, C. Cavin, and J.D. Hayes The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes Cancer Res. 61 2001 3299 3307 (Pubitemid 32695017)
25. T. Nguyen, P.J. Sherratt, and C.B. Pickett Regulatory mechanisms controlling gene expression mediated by the antioxidant response element Annu. Rev. Pharmacol. Toxicol. 43 2003 233 260 (Pubitemid 37372641)
26. A.D. Kraft, J.M. Lee, D.A. Johnson, Y.W. Kan, and J.A. Johnson Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element J. Neurochem. 98 2006 1852 1865 (Pubitemid 44298250)
27. J. Kirby, E. Halligan, M.J. Baptista, S. Allen, P.R. Heath, H. Holden, S.C. Barber, C.A. Loynes, C.A. Wood-Allum, J. Lunec, and P.J. Shaw Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS Brain 128 2005 1686 1706 (Pubitemid 41373687)
28. C.A. Wood-Allum, S.C. Barber, J. Kirby, P. Heath, H. Holden, R. Mead, A. Higginbottom, S. Allen, T. Beaujeux, S.E. Alexson, P.G. Ince, and P.J. Shaw Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen Brain 129 2006 1693 1709 (Pubitemid 43999404)
29. A. Sarlette, K. Krampfl, C. Grothe, N. Neuhoff, R. Dengler, and S. Petri Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis J. Neuropathol. Exp. Neurol. 67 2008 1055 1062
30. M.R. Vargas, D.A. Johnson, D.W. Sirkis, A. Messing, and J.A. Johnson Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis J. Neurosci. 28 2008 13574 13581
31. A.C. Ludolph, C. Bendotti, E. Blaugrund, A. Chio, L. Greensmith, J.P. Loeffler, R. Mead, H.G. Niessen, S. Petri, P.F. Pradat, W. Robberecht, M. Ruegg, B. Schwalenstocker, D. Stiller, L. van den Berg, F. Vieira, and S. von Horsten Guidelines for preclinical animal research in ALS/MND: A consensus meeting Amyotroph. Lateral Scler. 11 2010 38 45
32. W.S. Saari, and S.W. King Synthesis and biological activity of (6aS)-10,11-dihydroxyaporphine, the optical antipode of apomorphine J. Med. Chem. 16 1973 171 172
33. D. Raj, and M. Luczkiewicz Securinega suffruticosa Fitoterapia 79 2008 419 427
34. E. Sam, S. Sarre, Y. Michotte, and N. Verbeke Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid Eur J. Pharmacol. 329 1997 9 15 (Pubitemid 27264852)
35. E. Nicolle, P. Pollak, F. Serre-Debeauvais, P. Richard, C.L. Gervason, E. Broussolle, and M. Gavend Pharmacokinetics of apomorphine in parkinsonian patients Fundam. Clin. Pharmacol. 7 1993 245 252 (Pubitemid 23165333)
36. R.J. Mead, E.J. Bennett, A.J. Kennerley, P. Sharp, C. Sunyach, P. Kasher, J. Berwick, B. Pettmann, G. Battaglia, M. Azzouz, A. Grierson, and P.J. Shaw Optimised and rapid pre-clinical screening in the SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS) PLoS One 6 2011 e23244
37. R.N. Chakravarti, and D. Chakravarti Andrographolide, the active constituent of Andrographis paniculata Nees; a preliminary communication Ind. Med. Gaz 86 1951 96 97
38. A.Y. Woo, M.M. Waye, S.K. Tsui, S.T. Yeung, and C.H. Cheng Andrographolide up-regulates cellular-reduced glutathione level and protects cardiomyocytes against hypoxia/reoxygenation injury J. Pharmacol. Exp. Ther. 325 2008 226 235 (Pubitemid 351444632)
39. N.P. Trivedi, U.M. Rawal, and B.P. Patel Hepatoprotective effect of andrographolide against hexachlorocyclohexane-induced oxidative injury Integr. Cancer Ther 6 2007 271 280 (Pubitemid 47301120)
40. S. Daodee, J. Wangboonskul, K. Jarukamjorn, B.O. Sripanidkulchai, and T. Murakami Membrane transport of andrographolide in artificial membrane and rat small intestine Pak. J. Biol. Sci. 10 2007 2078 2085 (Pubitemid 47056180)
41. I. Tamai, and A. Tsuji Transporter-mediated permeation of drugs across the blood-brain barrier J. Pharm. Sci. 89 2000 1371 1388
42. M.J. Millan, L. Maiofiss, D. Cussac, V. Audinot, J.A. Boutin, and A. Newman-Tancredi Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes J. Pharmacol. Exp. Ther 303 2002 791 804 (Pubitemid 35231256)
43. N. Quinn Drug treatment of Parkinson's disease Br. Med. J 310 1995 575 579
44. E. Sam, A.P. Jeanjean, J.M. Maloteaux, and N. Verbeke Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application Eur. J. Drug Metab. Pharmacokinet. 20 1995 27 33
45. S.T. Gancher, W.R. Woodward, B. Boucher, and J.G. Nutt Peripheral pharmacokinetics of apomorphine in humans Ann. Neurol. 26 1989 232 238 (Pubitemid 19193092)
46. G. Bianchi, M. Landi, and S. Garattini Disposition of apomorphine in rat brain areas: relationship to stereotypy Eur. J. Pharmacol. 131 1986 229 236 (Pubitemid 17202489)
47. J. Lehmann, R.V. Smith, and S.Z. Langer Stereoisomers of apomorphine differ in affinity and intrinsic activity at presynaptic dopamine receptors modulating [3H]dopamine and [3H]acetylcholine release in slices of cat caudate Eur. J. Pharmacol 88 1983 81 88 (Pubitemid 13120869)
48. D.C. Hoffman, and R.J. Beninger The D1 dopamine receptor antagonist, SCH 23390 reduces locomotor activity and rearing in rats Pharmacol. Biochem. Behav. 22 1985 341 342 (Pubitemid 15132123)
49. M.J. Millan, A. Dekeyne, J.M. Rivet, T. Dubuffet, G. Lavielle, and M. Brocco S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626 J. Pharmacol. Exp. Ther. 293 2000 1063 1073 (Pubitemid 30417877)
50. M. Gassen, Y. Glinka, B. Pinchasi, and M.B. Youdim Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction Eur. J. Pharmacol. 308 1996 219 225 (Pubitemid 26237050)
51. 2-induced cell death Adv. Pharmacol 42 1998 320 324
52. E. Grunblatt, S. Mandel, G. Maor, and M.B. Youdim Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss J. Neurochem. 77 2001 146 156 (Pubitemid 32245088)
53. H. Hara, M. Ohta, and T. Adachi Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway J. Neurosci. Res 84 2006 860 866 (Pubitemid 44366687)
54. M.K. Kwak, N. Wakabayashi, K. Itoh, H. Motohashi, M. Yamamoto, and T.W. Kensler Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival J. Biol. Chem. 278 2003 8135 8145 (Pubitemid 36800555)
55. J.D. Hayes, M. McMahon, S. Chowdhry, and A.T. Dinkova-Kostova Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway Antioxid. Redox Signal. 13 2010 1713 1748
56. S. Da Cruz, P.A. Parone, V.S. Lopes, C. Lillo, M. McAlonis-Downes, S.K. Lee, A.P. Vetto, S. Petrosyan, M. Marsala, A.N. Murphy, D.S. Williams, B.M. Spiegelman, and D.W. Cleveland Elevated PGC-1alpha activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS Cell Metab. 15 2012 778 786
57. L.R. Fischer, D.G. Culver, P. Tennant, A.A. Davis, M. Wang, A. Castellano-Sanchez, J. Khan, M.A. Polak, and J.D. Glass Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man Exp. Neurol. 185 2004 232 240 (Pubitemid 38084849)
58. J. Schnabel Neuroscience: standard model Nature 454 2008 682 685
59. S. Scott, J.E. Kranz, J. Cole, J.M. Lincecum, K. Thompson, N. Kelly, A. Bostrom, J. Theodoss, B.M. Al-Nakhala, F.G. Vieira, J. Ramasubbu, and J.A. Heywood Design, power, and interpretation of studies in the standard murine model of ALS Amyotroph. Lateral Scler. 9 2008 4 15 (Pubitemid 351260367)
60. A. Neymotin, N.Y. Calingasan, E. Wille, N. Naseri, S. Petri, M. Damiano, K.T. Liby, R. Risingsong, M. Sporn, M.F. Beal, and M. Kiaei Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis Free Radic. Biol. Med. 51 2011 88 96
61. Z. Xu, S. Chen, X. Li, G. Luo, L. Li, and W. Le Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis Neurochem. Res. 31 2006 1263 1269 (Pubitemid 44701774)
62. J.M. Collins Phase 0 clinical studies in oncology Clin. Pharmacol. Ther. 85 2009 204 207
63. N.R. Cashman, H.D. Durham, J.K. Blusztajn, K. Oda, T. Tabira, I.T. Shaw, S. Dahrouge, and J.P. Antel Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons Dev. Dyn. 194 1992 209 221
64. M. Zhu, and W.E. Fahl Functional characterization of transcription regulators that interact with the electrophile response element Biochem. Biophys. Res. Commun. 289 2001 212 219 (Pubitemid 33108816)
65. S.C. Barber, A. Higginbottom, R.J. Mead, S. Barber, and P.J. Shaw An in vitro screening cascade to identify neuroprotective antioxidants in ALS Free Radic. Biol. Med. 46 2009 1127 1138
66. L.G. Higgins, M.O. Kelleher, I.M. Eggleston, K. Itoh, M. Yamamoto, and J.D. Hayes Transcription factor Nrf2 mediates an adaptive response to sulforaphane that protects fibroblasts in vitro against the cytotoxic effects of electrophiles, peroxides and redox-cycling agents Toxicol. Appl. Pharmacol. 237 2009 267 280
67. J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen. 4 1999 67 73 (Pubitemid 29278954)
68. R.P. Saneto, F. Chiappelli, and J. de Vellis Interleukin-2 inhibition of oligodendrocyte progenitor cell proliferation depends on expression of the TAC receptor J. Neurosci. Res 18 1987 147 154
69. P. Cassina, H. Peluffo, M. Pehar, L. Martinez-Palma, A. Ressia, J.S. Beckman, A.G. Estevez, and L. Barbeito Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis J. Neurosci. Res. 67 2002 21 29
70. D. Kieran, M. Hafezparast, S. Bohnert, J.R. Dick, J. Martin, G. Schiavo, E.M. Fisher, and L. Greensmith A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice J. Cell Biol. 169 2005 561 567 (Pubitemid 41002849)
71. P. Ertl, B. Rohde, and P. Selzer Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties J. Med. Chem 43 2000 3714 3717
72. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25 (Pubitemid 27046991)
73. R.K. Hoover, M.J. Kukulka, C.C. Kunwei, P.R. Velagaleti, B. Ronsen, and B.A. Bopp Plasma protein binding and whole blood distribution of apomorphine in plasma and blood from human, dog, rat and mouse 1999 Analytical BioChemistry Laboratories Columbia, MO
74. L.M. Berezhkovskiy Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination J. Pharm. Sci 93 2004 1628 1640 (Pubitemid 38725033)
75. C. Neef, and T. van Laar Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease Clin. Pharmacokinet 37 1999 257 271 (Pubitemid 29452757)
76. P.A. LeWitt Subcutaneously administered apomorphine: pharmacokinetics and metabolism Neurology 62 2004 S8 11